Potent  ||| S:0 E:7 ||| FW
phosphatidylinositol  ||| S:7 E:28 ||| FW
3-kinase  ||| S:28 E:37 ||| FW
inhibitors  ||| S:37 E:48 ||| FW
and  ||| S:48 E:52 ||| CC
their  ||| S:52 E:58 ||| PRP$
biology  ||| S:58 E:66 ||| NN
The  ||| S:66 E:70 ||| DT
Phosphoinositide  ||| S:70 E:87 ||| NNP
3-kinase  ||| S:87 E:96 ||| NNP
( ||| S:96 E:97 ||| -LRB-
PI3k ||| S:97 E:101 ||| NNP
)  ||| S:101 E:103 ||| -RRB-
is  ||| S:103 E:106 ||| VBZ
an  ||| S:106 E:109 ||| DT
important  ||| S:109 E:119 ||| JJ
regulator  ||| S:119 E:129 ||| NN
of  ||| S:129 E:132 ||| IN
intracellular  ||| S:132 E:146 ||| JJ
signalling  ||| S:146 E:157 ||| JJ
pathways ||| S:157 E:165 ||| NN
,  ||| S:165 E:167 ||| ,
like  ||| S:167 E:172 ||| IN
cell  ||| S:172 E:177 ||| NN
proliferation ||| S:177 E:190 ||| NN
,  ||| S:190 E:192 ||| ,
migration ||| S:192 E:201 ||| NN
,  ||| S:201 E:203 ||| ,
survival ||| S:203 E:211 ||| NN
,  ||| S:211 E:213 ||| ,
and  ||| S:213 E:217 ||| CC
angiogenesis  ||| S:217 E:230 ||| NN
upon  ||| S:230 E:235 ||| IN
activation  ||| S:235 E:246 ||| NN
by  ||| S:246 E:249 ||| IN
growth  ||| S:249 E:256 ||| NN
factor  ||| S:256 E:263 ||| NN
or  ||| S:263 E:266 ||| CC
receptors ||| S:266 E:275 ||| NNS
.  ||| S:275 E:277 ||| .
The  ||| S:277 E:281 ||| DT
PI3k ||| S:281 E:285 ||| NNP
's  ||| S:285 E:288 ||| POS
pathway  ||| S:288 E:296 ||| NN
is  ||| S:296 E:299 ||| VBZ
frequently  ||| S:299 E:310 ||| RB
up-regulated  ||| S:310 E:323 ||| JJ
in  ||| S:323 E:326 ||| IN
human  ||| S:326 E:332 ||| JJ
cancers ||| S:332 E:339 ||| NNS
,  ||| S:339 E:341 ||| ,
thus  ||| S:341 E:346 ||| RB
inhibition  ||| S:346 E:357 ||| VBN
of  ||| S:357 E:360 ||| IN
PI3k ||| S:360 E:364 ||| NNP
's  ||| S:364 E:367 ||| POS
is  ||| S:367 E:370 ||| VBZ
a  ||| S:370 E:372 ||| DT
promising  ||| S:372 E:382 ||| JJ
approach  ||| S:382 E:391 ||| NN
for  ||| S:391 E:395 ||| IN
cancer  ||| S:395 E:402 ||| NN
therapy ||| S:402 E:409 ||| NN
.  ||| S:409 E:411 ||| .
Many  ||| S:411 E:416 ||| JJ
potent  ||| S:416 E:423 ||| JJ
PI3k ||| S:423 E:427 ||| NNP
's  ||| S:427 E:430 ||| POS
inhibitors  ||| S:430 E:441 ||| NNS
have  ||| S:441 E:446 ||| VBP
been  ||| S:446 E:451 ||| VBN
reported  ||| S:451 E:460 ||| VBN
so  ||| S:460 E:463 ||| RB
far  ||| S:463 E:467 ||| RB
and  ||| S:467 E:471 ||| CC
few  ||| S:471 E:475 ||| JJ
of  ||| S:475 E:478 ||| IN
them  ||| S:478 E:483 ||| PRP
are  ||| S:483 E:487 ||| VBP
in  ||| S:487 E:490 ||| IN
clinical  ||| S:490 E:499 ||| JJ
trial  ||| S:499 E:505 ||| NN
like  ||| S:505 E:510 ||| IN
GDC-0941 ||| S:510 E:518 ||| NNP
,  ||| S:518 E:520 ||| ,
BGT-226 ||| S:520 E:527 ||| NNP
,  ||| S:527 E:529 ||| ,
AZD-6482  ||| S:529 E:538 ||| NNP
and  ||| S:538 E:542 ||| CC
others  ||| S:542 E:549 ||| NNS
are  ||| S:549 E:553 ||| VBP
natural  ||| S:553 E:561 ||| JJ
products  ||| S:561 E:570 ||| NNS
etc ||| S:570 E:573 ||| NN
.  ||| S:573 E:575 ||| .
